Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341129 · ClinicalTrials.gov registry record · Early Phase 1
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT04341129: Completed Early Phase 1 study, sponsored by University of Chicago.
NCT04341129 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 50 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04341129, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. There are also promising results of ultrafast DCE-MRI studies with shorter breast MRI protocols that provide not only morphologic but also valuable kinetic information about a lesion. The shorter imaging times achieved with the abbreviated and the ultrafast DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol with ultrafast imaging using Dotarem® (Gadoterate Meglumine).
Primary Outcome
The abbreviated protocol will be generated from the full diagnostic protocol. It will comprise of a single unenhanced sequence and a single contrast-enhanced sequence. Subtraction images and a maximum intensity projection (MIP) image will be generated post-examination. The novel kinetic information obtained from the early contrast in combination with morphologic information from a high spatial resolution post-contrast scan, may provide unique dynamic parameters to effectively characterize and di
Interventions
- DRUG Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2023-06-30 |
| Phase | Early Phase 1 |
What the finished NCT04341129 record still lists
NCT04341129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine) is the first listed.
NCT04341129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04341129 about?
NCT04341129 is a clinical study titled "Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)". Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. There are ...
What is the current status of trial NCT04341129?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2020-07-13. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04341129?
The interventions under investigation include: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine) (DRUG).
Who is sponsoring clinical trial NCT04341129?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04341129's enrollment target sits among peer trials
50 493rd of 2000 higher than 1,468 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI